01
Sense
Surface receptors read antigen and cytokine context together, not a single marker in isolation.
Programmable cell therapy
Therapies that wait for the signal.
We engineer immune cells with synthetic gene circuits — living medicines that sense a tumor or autoimmune flare, then act only there.
Innovation
A cell should know the difference.
Conventional cell therapies fire too broadly. Toxicity follows. Aetheris builds genetic circuits that require the right combination of disease cues before a cell releases its payload — then shut down when the signal fades.
02
Circuit
Synthetic logic — AND, NOT, threshold — decides whether the microenvironment is truly disease.
03
Act
Cytotoxic or regulatory payload is released locally. Off-target tissue stays quiet.
How an Aetheris cell works
Platform
How an Aetheris cell works
Four molecular events. One living medicine. Scroll the sequence to see a circuit arm, fire, and resolve.
01
Antigen & cytokine sensing
Custom receptor pairs sit in the membrane and sample the tissue continuously. A single cue is never enough. Coincidence of disease-associated signals is required before the circuit even considers firing.
02
Genetic logic assembly
Inside the cell, synthetic promoters and RNA gates compute. AND, NOT, and threshold modules filter noise — the same way a healthy immune system distinguishes self from threat, only written on purpose.
03
Localized effector release
When logic is satisfied, secretory vesicles dock and release a defined payload at the immune synapse. Neighboring diseased cells are engaged. Distant, healthy tissue is not.
04
Signal-off resolution
As antigen and inflammatory cues recede, the circuit damps. Effector programs wind down. The living medicine does not linger as an ungoverned weapon.
Capabilities
Built for partners who need more than a construct.
We co-develop programmable cell programs from first circuit to translational package — with the same discipline we use on our internal pipeline.
01
Circuit discovery
Disease-context mapping and receptor logic design for solid tumors, autoimmunity, and inflammation.
02
Cell engineering
Primary immune-cell modification, circuit insertion, and functional QC in physiologically relevant models.
03
Translational development
Biodistribution, on/off-target quantification, and CMC-minded process work that survives diligence.
04
Co-development
Shared programs with biopharma — from optioned circuits to jointly governed living medicines.
Impact
Selectivity you can measure.
Preclinical packages, not slogans. Figures below are from gated-circuit models versus unmatched conventional CARs in matched assays.
0
Circuit architectures in preclinical
0
Clinical-path indications
0%
Off-target silence in models
0×
Selectivity vs. ungated CAR-T
Partnership
Bring us a target. We’ll bring the circuit.
Scientific inquiries, collaboration proposals, and translational partners — we read every note. Tell us the disease context; we’ll tell you if a gated cell is the right instrument.
science@aetheris.bio